Protection for an unpredictable world

We are developing cutting-edge vaccines by utilizing our innovative adjuvant technology and  our expertise of Toll-like Receptor (TLR) biology to modulate the immune system.

TLR Biology

HEPLISAV-B®
[HEPATITIS B VACCINE (RECOMBINANT) ADJUVANTED]

COVID-19 Information and Resources

During the uncertainty caused by the COVID-19 pandemic, Dynavax has acted quickly to focus on four key areas – these include safeguarding the health and safety of our employees and customers; continuing effective operations to ensure patient access to HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted]; maintaining our financial strength and stability; and supporting efforts to develop a COVID-19 vaccine.

learn more.